Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Azole antifungal sensitivity of sterol 14α-demethylase (cyp51) and cyp5218 from Malassezia globosa

Warrilow, Andrew G. S., Price, Claire L., Parker, Josie E., Rolley, Nicola J., Smyrniotis, Christopher J., Hughes, David D., Thoss, Vera, Nes, W. David, Kelly, Diane E., Holman, Theodore R. and Kelly, Steven L. 2016. Azole antifungal sensitivity of sterol 14α-demethylase (cyp51) and cyp5218 from Malassezia globosa. Scientific Reports 6 (1) , 27690. 10.1038/srep27690

[thumbnail of Azole Antifungal Sensitivity of Sterol 14?-Demethylase (CYP51) and CYP5218 from Malassezia globose.pdf]
PDF - Published Version
Available under License Creative Commons Attribution.

Download (974kB) | Preview


Malassezia globosa cytochromes P450 CYP51 and CYP5218 are sterol 14α-demethylase (the target of azole antifungals) and a putative fatty acid metabolism protein (and a potential azole drug target), respectively. Lanosterol, eburicol and obtusifoliol bound to CYP51 with Kd values of 32, 23 and 28 μM, respectively, catalyzing sterol 14α-demethylation with respective turnover numbers of 1.7 min−1, 5.6 min−1 and 3.4 min−1. CYP5218 bound a range of fatty acids with linoleic acid binding strongest (Kd 36 μM), although no metabolism could be detected in reconstitution assays or role in growth on lipids. Clotrimazole, fluconazole, itraconazole, ketoconazole, voriconazole and ketaminazole bound tightly to CYP51 (Kd ≤ 2 to 11 nM). In contrast, fluconazole did not bind to CYP5218, voriconazole and ketaminazole bound weakly (Kd ~107 and ~12 μM), whereas ketoconazole, clotrimazole and itraconazole bound strongest to CYP5218 (Kd ~1.6, 0.5 and 0.4 μM) indicating CYP5218 to be only a secondary target of azole antifungals. IC50 determinations confirmed M. globosa CYP51 was strongly inhibited by azole antifungals (0.15 to 0.35 μM). MIC100 studies showed itraconazole should be considered as an alternative to ketoconazole given the potency and safety profiles and the CYP51 assay system can be used in structure-activity studies in drug development.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Biosciences
Publisher: Nature Research
ISSN: 2045-2322
Date of First Compliant Deposit: 8 July 2022
Date of Acceptance: 23 May 2016
Last Modified: 18 May 2023 02:34

Citation Data

Cited 9 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics